RealFeedApp Resolution Therapeutics reports 42 percent relative risk reduction
In the Phase I/II EMERALD trial, RTX001 showed a 42 percent relative risk reduction in the composite endpoint of death, liver transplant, or hepatic decompensation compared to standard-of-care patients. The drug was well tolerated with no infusion-related serious adverse reactions.
- Field
- ageing and longevity
- What they did
- Researchers demonstrated that the drug RTX001 significantly reduces the risk of death or liver transplant in patients with end-stage liver disease, without causing serious side effects.
- Why it matters
- This result could serve as a foundation for developing new treatments that extend the lives of people with severe liver conditions.
#resolution therapeutics#rtx001#emerald trial#liver disease#phase i/ii
